Prognostic Value of Circulating Fibrosis Biomarkers in Dilated Cardiomyopathy (DCM): Insights into Clinical Outcomes
Circulating fibrosis biomarkers, particularly MMP-2, TIMP-1, GDF-15, and OPN, are valuable prognostic tools in DCM. They reflect the severity of myocardial remodeling and systemic disease burden, aiding in risk stratification and therapeutic intervention. Integrating these biomarkers into clinical practice could improve DCM management and patient prognosis.
Authors
- Norbert Frey (ORCID: https://orcid.org/0000-0001-7611-378X)
- Daniel Tian Li
- Benjamin Meder (ORCID: https://orcid.org/0000-0003-0741-2633)
- T Miersch (ORCID: https://orcid.org/0000-0002-0453-0960)
- Tanja Weis
- Imo E. Hoefer (ORCID: https://orcid.org/0000-0002-8379-7814)
- Farbod Sedaghat‐Hamedani (ORCID: https://orcid.org/0000-0002-3266-0527)
- Elham Kayvanpour (ORCID: https://orcid.org/0000-0001-7285-2825)
Institutions
- Heidelberg University (DE)
- University Medical Center Utrecht (NL)
- German Centre for Cardiovascular Research (DE)
- Klaus Tschira Foundation (DE)
Publication Details
- Journal
- Biomolecules
- Published
- 2024-09-09
- DOI
- https://doi.org/10.3390/biom14091137
- Citations
- 7
- Primary Topic
- GDF15 and Related Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 3.29